A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer

NCT04611724 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Urachal Cancer

Interventions

DRUG: FOLFIRINOX

Sponsor

Asan Medical Center

Collaborators

[object Object]
[object Object]